- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Michel Michaelides Speaks About Implications of Gene Therapy Study Results in Ophthalmology
The results of a study showing improved functional vision and retinal sensitivity have implications for gene therapy in ophthalmological conditions, explained Michel Michaelides, MD, FACP, a consultant ophthalmologist and a professor of ophthalmology at the University College London Institute of Ophthalmology's Genetics Department.
Michel Michaelides, MD, FACP, explained what research findings presented at the American Academy of Ophthalmology (AAO) 2022 Conference could mean for the potential of gene therapy to improve functional vision and retinal sensitivity in patients with retinitis pigmentosa.
Transcript
What were some of the results from your study that was presented at AAO 2022 and what do they say about the potential for the investigational gene therapy botaretigene sparoparvovec (bota-vec)?
We presented our phase 1/2 data of the entire trial and also including the randomized controlled expansion phase. And what was exciting was that, in addition to the safety that we've previously alluded to, we were able to show that, comparing treated patients to a concurrent control group, there were significant improvements in both retinal sensitivity and functional vision. And I was particularly excited about the functional vision because that's what patients can do with the improvement in their retinal sensitivity and, arguably, that's the most important thing.
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Advancing Integrated Care for Comorbid Schizophrenia and Substance Use Disorder
February 11th 2025Joshua Kaufman, MD, medical director of Behavioral Health and Medical Integration at Capital District Physicians' Health Plan, outlines the progression of treatment approaches for comorbid schizophrenia and substance use disorder.
Read More
